B
Bull
Bull · 25%ADGM
$1.53
Scenario price
$0.099
-0.004 (-3.88%)At close
Loading chart…
- High
- 0.106
- Open
- 0.101
- VWAP
- 0.10
- Volume
- 626.07K
- Mkt Cap
- —
- Low
- 0.095
- Amount
- 62.67K
- EV/EBITDA, TTM
- 0.00
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation.
AI analysis of Adagio Medical Holdings Inc (ADGM)
SellAdagio Medical Holdings Inc is not a good buy right now due to significant financial losses and a very low RSI of 12.485, indicating oversold conditions. The stock has dropped 93.19% over the past year, and while there is some analyst optimism with a $3 target, the current price of $0.13 does not justify the risk given the company's ongoing negative earnings and high debt levels.
Valuation Metrics
The current forward P/E ratio for Adagio Medical Holdings Inc (ADGM) is 0.00, compared to its 5-year average forward P/E of -0.07.
Alphio AI Price Scenarios for ADGM
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ADGM
Events Timeline
News
8.509-23NewsfilterAdagio Advances PMA Application for vCLAS System Amid Strategic Review
- 8.509-16Newsfilter
Adagio Medical Advances Next-Gen ULTRA Catheter Study
- 5.009-08Newsfilter
Teleflex Appoints New Board Member Sean M. Salmon
- 9.508-11Newsfilter
Adagio Medical Reports Q2 2026 Financial Results and Key Developments
5.008-04NASDAQ.COMAdagio Medical Successfully Treats First Patient with Next-Gen Ablation System
ADGM FAQ — answered by Alphio AI
Adagio Medical Holdings, Inc. is a medical device company. The Company is focused on developing and commercializing products for the treatment of cardiac arrhythmias with catheter-based ultra-low temperature ablation (ULTA) technology, formerly known as ultra-low temperature cryoablation (ULTC) technology. Its initial focus is on the treatment of ventricular tachycardia (VT), which is a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart’s lower chambers, or ventricles, potentially leading to impaired blood flow and, if sustained, it can be fatal. Its ULTA products are purpose-built to treat patients with VT and are designed to address the unique anatomy of the ventricle and the specific needs of the VT patient. Its catheters and consoles are designed to create titratable, large, durable, deep lesions within the ventricle through a stable, endocardial or inside the heart approach with no required irrigation. It operates in the Healthcare sector.
Adagio Medical Holdings Inc is not a good buy right now due to significant financial losses and a very low RSI of 12.485, indicating oversold conditions. The stock has dropped 93.19% over the past year, and while there is some analyst optimism with a $3 target, the current price of $0.13 does not justify the risk given the company's ongoing negative earnings and high debt levels.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.